MIPI Score Calculator

MIPI Score Calculator for Hematology. MIPI sorts patients into three groups with markedly divergent survival: in the 958-patient validation, 5-year overall survival was about 83% (low), 63% (intermediate), and 34% (high), with each step up roughly 2 to 2.6-fold increasing the hazard of death. A low score signals durable remission potential with standard immunochemotherapy, while a high score flags patients for whom intensified or clinical-trial approaches and closer surveillance are reasonable. Because age dominates the arithmetic, an elderly patient with otherwise benign features can reach intermediate risk; conversely a young patient needs a very high LDH ratio, high WBC, or poor performance status to be classified high risk. The score describes prognosis, not chemosensitivity, so pair it with Ki-67 and TP53 status, which independently worsen outcome even within a favorable MIPI band.

How this calculator works

The MIPI (Mantle Cell Lymphoma International Prognostic Index) combines four baseline variables into a single weighted prognostic score: age in years, ECOG performance status (0-1 vs 2-4), serum LDH expressed as a ratio to the local upper limit of normal, and white blood cell count. The three continuous inputs (age, log LDH ratio, log WBC) are entered into a Cox-regression-derived linear predictor with fixed coefficients, and a fixed increment is added when ECOG is 2 or higher. The resulting continuous score is banded into low, intermediate, and high risk. A biological variant (MIPIb) incorporates the Ki-67 proliferation index for tumors with available immunostaining, which sharpens discrimination.

When to use this calculator

Use MIPI at diagnosis for adults with histologically confirmed mantle cell lymphoma to stratify baseline prognosis before first-line therapy and to standardize risk description in trials and tumor boards. It is the MCL-specific analog of the IPI and is endorsed for routine use in ESMO and NCCN MCL guidance. It is not a treatment-selection algorithm on its own, is not validated for other lymphoma subtypes, and should not be applied at relapse or used to withhold curative-intent therapy; leukemic non-nodal and indolent MCL variants can be over-classified by a high WBC.

Inputs used

Age
ECOG performance status
LDH
White blood cell count

Clinical interpretation

MIPI sorts patients into three groups with markedly divergent survival: in the 958-patient validation, 5-year overall survival was about 83% (low), 63% (intermediate), and 34% (high), with each step up roughly 2 to 2.6-fold increasing the hazard of death. A low score signals durable remission potential with standard immunochemotherapy, while a high score flags patients for whom intensified or clinical-trial approaches and closer surveillance are reasonable. Because age dominates the arithmetic, an elderly patient with otherwise benign features can reach intermediate risk; conversely a young patient needs a very high LDH ratio, high WBC, or poor performance status to be classified high risk. The score describes prognosis, not chemosensitivity, so pair it with Ki-67 and TP53 status, which independently worsen outcome even within a favorable MIPI band.

Worked example

Consider a 68-year-old with ECOG 1, LDH 320 U/L against a local ULN of 250 U/L (ratio 1.28), and WBC 9.5 x10^9/L. Advanced age contributes the largest weight, the modestly elevated LDH ratio and near-normal WBC add small increments, and normal performance status adds nothing. This combination lands in the intermediate-risk band, corresponding in the pooled European MCL Network validation to roughly a 63% 5-year overall survival, versus about 83% for low risk and 34% for high risk.

Limitations and safety notes

MIPI was derived and validated in patients treated with rituximab-containing immunochemotherapy eras and predates BTK inhibitors, CAR-T, and modern minimal-residual-disease-guided strategies, so absolute survival estimates may understate outcomes today. It captures none of the high-risk biology that drives early failure: TP53 mutation/deletion, blastoid/pleomorphic morphology, and high Ki-67 can produce poor outcomes despite a low or intermediate clinical MIPI. LDH ratio depends on the local assay ULN, and a leukemic presentation can inflate the WBC term in otherwise indolent leukemic non-nodal MCL, both introducing misclassification.

Frequently asked questions

What is the difference between MIPI and MIPIb?

MIPIb (biological MIPI) adds the Ki-67 proliferation index to the four clinical MIPI variables. Ki-67 is an independent prognostic marker, so MIPIb separates risk groups more sharply when reliable immunostaining is available; the clinical MIPI is used when Ki-67 is not.

Does a low MIPI mean the patient can avoid intensive therapy?

No. MIPI estimates prognosis, not chemosensitivity or the need for a specific regimen. A low score predicts better survival on standard therapy but does not license de-escalation, and high-risk biology such as TP53 aberration can coexist with a low score.

How is the LDH value entered?

As a ratio of the measured serum LDH to the local laboratory upper limit of normal, not the raw value. This normalizes across assays with different reference ranges before the log-transformed ratio enters the formula.

Can MIPI be used at relapse or for other lymphomas?

No. It was derived and validated for baseline risk in newly diagnosed mantle cell lymphoma only. It is not validated at relapse or in other non-Hodgkin lymphoma subtypes, where the IPI or subtype-specific indices apply.

References

Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565. PMID: 17962512.
Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32(13):1338-1346. PMID: 24687837.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: May 12, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

Prefer original validation studies for scoring systems and prediction tools.
Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.